Role of modeling and simulation in pediatric investigation plans
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Ethical and practical constraints encourage the optimal use of resources in pediatric drug development. Modeling and simulation has emerged as a promising methodology acknowledged by industry, academia, and regulators. We previously proposed a paradigm in pediatric drug development, whereby modeling and simulation is used as a decision tool, for study optimization and/or as a data analysis tool. Three and a half years since the Paediatric Regulation came into force in 2007, the European Medicines Agency has gained substantial experience in the use of modeling and simulation in pediatric drug development. In this review, we present examples on how the proposed paradigm applies in real case scenarios of planned pharmaceutical developments. We also report the results of a pediatric database search to further ‘validate’ the paradigm. There were 47 of 210 positive pediatric investigation plan (PIP) opinions that made reference to modeling and simulation (data included all positive opinions issued up to January 2010). This reflects a major shift in regulatory thinking. The ratio of PIPs with modeling and simulation rose to two in five based on the summary reports. Population pharmacokinetic (POP‐PK) and pharmacodynamics (POP‐PD) and physiologically based pharmacokinetic models are widely used by industry and endorsed or even imposed by regulators as a way to circumvent some difficulties in developing medicinal products in children. The knowledge of the effects of age and size on PK is improving, and models are widely employed to make optimal use of this knowledge but less is known about the effects of size and maturation on PD, disease progression, and safety. Extrapolation of efficacy from different age groups is often used in pediatric medicinal development as another means to alleviate the burden of clinical trials in children, and this can be aided by modeling and simulation to supplement clinical data. The regulatory assessment is finally judged on clinical grounds such as feasibility, ethical issues, prioritization of studies, and unmet medical need. The regulators are eager to expand the use of modeling and simulation to elucidate safety issues, to evaluate the effects of disease (e.g., renal or hepatic dysfunction), and to qualify mechanistic models that could help shift the current medicinal development paradigm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fourth Dimension of Life: Fractal Geometry and Allometric Scaling of Organisms
West, G. B., Brown, J. H., & Enquist, B. J. (1999) · Science · doi:10.1126/science.284.5420.1677 · Cited by 1,718
Cited by
Developmental Pharmacokinetics in Pediatric Populations
Lu, H., & Rosenbaum, S. (2014) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-19.4.262 · Cited by 358
Smits, A., Annaert, P., Cavallaro, G., De Cock, P. A. J. G., de Wildt, S. N., Kindblom, J. M., Lagler, F. B., Moreno, C., Pokorna, P., Schreuder, M. F., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14958 · Cited by 55
Michelet, R., Bindellini, D., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Johnson, T. N., Whitaker, M. J., Ross, R., & Kloft, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1090554 · Cited by 5
Metadata
- Authors
- Manolis, E., Osman, T. E., Herold, R., Koenig, F., Tomasi, P., Vamvakas, S., & Raymond, A. S.
- Venue
- Pediatric Anesthesia
- Publisher
- Wiley
- Published
- 2011-01-18
- Volume
- 21
- Issue
- 3
- Pages
- 214-221
- ISSN
- 1155-5645 (ISSN-L)
- 1460-9592
- OpenAlex
- W1797500306
- Cited by
- 84
- References
- 1
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of modeling and simulation in pediatric investigation plans. https://app.cochat.ai/papers/10.1111/j.1460-9592.2011.03523.x
- The paper
- Manolis, E., Osman, T. E., Herold, R., Koenig, F., Tomasi, P., Vamvakas, S., & Raymond, A. S. (2011). Role of modeling and simulation in pediatric investigation plans. Pediatric Anesthesia. https://doi.org/10.1111/j.1460-9592.2011.03523.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.